ESR1 and neoplasm: In this study, RYNXC could significantly decrease ESR1, PGR, EGFR, PTGS2, and Src mRNA expressions in a dose-dependent manner in MCF-10AT cells or breast precancerous lesion model rats, which could further inhibit cell proliferation and tumor progression.